LONDON, October 6, 2021 / PRNewswire-PRWeb / – Company Adopted Generis’ CARA Platform for Ongoing Work to Answer Questions from Health Authorities Around the World, Leveraging the Platform’s Powerful Automation and Translation Capabilities -form CARA Life Science to capture, review and answer regulatory questions.
The questions will be individually extracted from the incoming documents and then translated into multiple languages, providing Kyowa Kirin with a multilingual database of questions from medical authorities, so that users around the world can find answers in any language.
Commenting on the partnership, James kelleher, CEO of Generis, said, “We are delighted to have the opportunity to work with Kyowa Kirin to bring their products to market using the CARA Life Sciences platform to ensure consistent communications with health authorities while reducing the burden. day-to-day operations. “
The CARA Life Sciences platform has seen intense activity in recent months as pharmaceutical companies seek to streamline the management and publication of regulatory, quality, safety and clinical information / content using a cohesive global platform that can be easily configured to suit everyone. new use case.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver new medicines with life changing value. Like a JapanGlobal Specialty Pharmaceutical Company With a heritage of over 70 years, the company applies cutting-edge science, including expertise in antibody research and engineering, to meet the needs of patients and society across multiple therapeutic areas. , including nephrology, oncology, immunology / allergy and neurology. In its four regions – Japan, Asia Pacific, North America and EMEA / International – we are focused on its purpose, making people smile, and are united by our common values ​​of Commitment to Life, Teamwork / Wa, Innovation and Integrity. You can find out more about Kyowa Kirin’s business at https://www.kyowakirin.com
About Generis
Generis is a UK-based developer of world-class content and data management technologies for globally regulated industries.
60% of Top 20 Life Sciences Companies rely on Generis’ flagship CARA â„¢ Life Science Platform for management of critical documents and information, including AbbVie, AstraZeneca, Biogen, Gilead, Bayer, Pfizer and Merck KGaA.
Today, Generis serves more than 600,000 users worldwide, in use cases ranging from RIM, regulatory / R&D and safety use cases to clinical, non-clinical, GxP quality, CMC, pharmacovigilance, medical information applications. / medical affairs and more. More on generiscorp.com
Press contact for Generis
Carina Birt, Sarum PR
+44 7970 006624
Media contact
Carina Birt, Sarum PR, +44 7970006624, [email protected]
Gillian reading, Sarum PR, 7799153550, [email protected]
SOURCE Generis
